MTN-017 was a Phase II trial designed to evaluate the rectal safety, drug absorption and acceptability of a reduced glycerin formulation of tenofovir gel, as well as oral Truvada as daily oral PrEP, at sites in Peru, South Africa, Thailand and the U.S., including Puerto Rico. The study enrolled 195 cisgender men and transgender women who have sex with men. Results, which were reported February 2016, found the gel was safe to use, with participants preferring to use the gel around the time of sex as opposed to daily, but that they were also more likely to use daily oral PrEP than a daily gel.
Results
International Study Finds High Levels of Adherence to Use of Rectal Microbicide Gel
20-October-2016
24-February-2016
24-February-2016
See Also
Rectal Microbicides – Fact Sheet
21-Apr-2020
International Study Finds Rectal Microbicide Gel Safe When Used Daily and With Sex
24-February-2016
VIDEO – The Rectal Revolution is Here
Other Study Milestones
Researchers Launch First-Ever Phase II Safety Study of a Rectal Microbicide to Prevent HIV
02-October-2013
Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial
3-April-2013
9-January-2013
Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use
17-May-2012
Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study
5-March-2012